The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas

Bibliography

• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Mourelatos Z, Dostie J, Paushkin S, et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002;16:720–728.
   PubMed Web of Science ®Google Scholar
• Friedman R, Farh K. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
   PubMed Web of Science ®Google Scholar
• Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2013;31:577.
   PubMed Web of Science ®Google Scholar
• Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17:193–199.
   PubMed Web of Science ®Google Scholar
• Song R, Walentek P, Sponer N, et al. miR-34/449 miRNAs are required for motile ciliogenesis by repressing cp110. Nature. 2014;510:115–120.
   PubMed Web of Science ®Google Scholar
• Wu J, Bao J, Kim M, et al. Two miRNA clusters, miR-34b/c and miR-449, are essential for normal brain development, motile ciliogenesis, and spermatogenesis. Proc Natl Acad Sci USA. 2014;111:E2851–E2857.
   Google Scholar
• Bao J, Li D, Wang L, et al. MicroRNA-449 and microRNA-34b/c function redundantly in murine testes by targeting E2F transcription factor-retinoblastoma protein (E2F-pRb) pathway. J Biol Chem. 2012;287:21686–21698.
   PubMed Web of Science ®Google Scholar
• Xiaojing Y, Min F, Xia J, et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 2009;23:2388–2393.
   PubMed Web of Science ®Google Scholar
• Marcet B, Chevalier B, Luxardi G, et al. Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. Nat Cell Biol. 2011;13:693–699.
   PubMed Web of Science ®Google Scholar
• Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer. 2011;10:29.
   PubMed Web of Science ®Google Scholar
• Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586–1593.
   PubMed Web of Science ®Google Scholar
• Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. Elsevier. 2007;17:1298–1307.
   PubMed Web of Science ®Google Scholar
• Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731–743.
   PubMed Web of Science ®Google Scholar
• He L, He X, Lowe SW, et al. microRNAs join the p53 network–another piece in the tumour-suppression puzzle. Nat Rev Cancer. 2007;7:819–822.
   PubMed Web of Science ®Google Scholar
• Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–752.
   PubMed Web of Science ®Google Scholar
• Kato M, Paranjape T, Müller RU, et al. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 2009;28:2419–2424.
   PubMed Web of Science ®Google Scholar
• Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA. 2008;105:13421–13426.
   PubMed Web of Science ®Google Scholar
• Kumar B, Yadav A, Lang J, et al. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One. 2012;7:e37601.
   PubMed Web of Science ®Google Scholar
• Stallings RL. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des. 2009;15:456–462.
   PubMed Web of Science ®Google Scholar
• Akao Y, Noguchi S, Iio A, et al. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 2011;300:197–204.
   PubMed Web of Science ®Google Scholar
• Roy S, Levi E, Majumdar APN, et al. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 2012;5:58.
   PubMed Web of Science ®Google Scholar
• Misso G, Teresa M, Martino D, et al. Mir-34 : a new weapon against cancer ? Mol Ther Nucleic Acids. 2014;3:e194.
   PubMedGoogle Scholar
• Merkel O, Asslaber D, Piñón JD, et al. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle. 2010;9:2764–2768.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Kojima K, Hamada N, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008;377:114–119.
   PubMed Web of Science ®Google Scholar
• Kojima K, Fujita Y, Nozawa Y, et al. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate. 2010;70:1501–1512.
   PubMed Web of Science ®Google Scholar
• Siemens H, Jackstadt R, Hünten S, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle. 2011;10:4256–4271.
   PubMed Web of Science ®Google Scholar
• Rokavec M, Öner MG, Li H, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014;124:1853–1867.
   PubMed Web of Science ®Google Scholar
• Navarro F, Gutman D, Meire E, et al. miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood. 2009;114:2181–2192.
   PubMed Web of Science ®Google Scholar
• Ichimura A, Ruike Y, Terasawa K, et al. MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells. Mol Pharmacol. 2010;77:1016–1024.
   PubMed Web of Science ®Google Scholar
• Pulikkan JA, Peramangalam PS, Dengler V, et al. C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood. 2010;116:5638–5649.
   PubMed Web of Science ®Google Scholar
• Yang F, Li Q, Gong Z, et al. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat. 2013;13:77–86.
   PubMed Web of Science ®Google Scholar
• Wiggins JF, Ruffino L, Kelnar K, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70:5923–5930.
   PubMed Web of Science ®Google Scholar
• Corcoran C, Rani S, O’Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014;74:1320–1334.
   PubMed Web of Science ®Google Scholar
• Zhao G, Guo J, Li D, et al. MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer MCF-7 cell line. DNA Cell Biol. 2013;00:1–9.
   Google Scholar
• Boon RA, Iekushi K, Lechner S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495:107–110.
   PubMed Web of Science ®Google Scholar
• Park EY, Chang E, Lee EJ, et al. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res. 2014;74:7573–7582.
   PubMed Web of Science ®Google Scholar
• Bu P, Chen K-Y, Chen JH, et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell. 2013;12:602–615.
   PubMed Web of Science ®Google Scholar
• Wu M-Y, Fu J, Xiao X, et al. MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. Cancer Lett. 2014;354:311–319.
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y, Gao J, et al. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene. 2012;32:4294–4303.
   Web of Science ®Google Scholar
• Wu J, Wu G, Lv L, et al. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis. 2012;33:519–528.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhou J, Dong M. Dysregulation of microRNA-34a expression in colorectal cancer inhibits the phosphorylation of FAK via VEGF. Dig Dis Sci. 2014;59:958–967.
   PubMed Web of Science ®Google Scholar
• Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211–215.
   PubMed Web of Science ®Google Scholar
• Tryndyak VP, Ross SA, Beland FA, et al. Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol Carcinog. 2009;48:479–487.
   PubMed Web of Science ®Google Scholar
• Craig VJ, Cogliatti SB, Imig J, et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011;117:6227–6236.
   PubMed Web of Science ®Google Scholar
• Hau A, Ceppi P, Peter ME. CD95 is part of a let-7/p53/miR-34 regulatory network. PLoS One. 2012;7:e49636.
   Web of Science ®Google Scholar
• Concepcion CP, Han Y-C, Mu P, et al. Intact p53-dependent responses in miR-34-deficient mice. Grimes HL, editor. PLoS Genet. Public Library of Science; 2012; 8:e1002797.
   PubMed Web of Science ®Google Scholar
• Mraz M, Malinova K, Kotaskova J, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009;23:1159–1163.
   PubMed Web of Science ®Google Scholar
• Dijkstra MK, Van Lom K, Tielemans D, et al. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia. 2009;23:625–627.
   PubMed Web of Science ®Google Scholar
• Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014;24:R762–R776.
   PubMed Web of Science ®Google Scholar
• Li XJ, Ren ZJ, Tang JH. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis. 2014;5:e1327.
   PubMed Web of Science ®Google Scholar
• Wang X, Li J, Dong K, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015;27:443–452.
   PubMed Web of Science ®Google Scholar
• Jacob ST. Breast cancer. Introduction. Gene Expr. 2011;15:103.
   PubMed Web of Science ®Google Scholar
• Eichelser C, Flesch-Janys D, Chang-Claude J, et al. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem. 2013;59:1489–1496.
   PubMed Web of Science ®Google Scholar
• Frères P, Josse C, Bovy N, et al. Neoadjuvant chemotherapy in breast cancer patients induces miR-34a and miR-122 expression. J Cell Physiol. 2014;230:473–481.
   Web of Science ®Google Scholar
• Javeri A, Ghaffarpour M, Taha MF, et al. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. Med Oncol. 2013;30:413.
   PubMed Web of Science ®Google Scholar
• Mackiewicz M, Huppi K, Pitt JJ, et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 2011;130:663–679.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. American Society for Clinical Investigation. 2011;121:2750–2767.
   PubMed Web of Science ®Google Scholar
• Li XJ, Ji MH, Zhong SL, et al. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting notch1. Arch Med Res. 2012;43:514–521.
   PubMed Web of Science ®Google Scholar
• Deng X, Cao M, Zhang J, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 2014;35:4333–4344.
   PubMed Web of Science ®Google Scholar
• Kastl L, Brown I, Schofield AC. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat. 2012;131:445–454.
   PubMed Web of Science ®Google Scholar
• Li L, Yuan L, Luo J, et al. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013;13:109–117.
   PubMed Web of Science ®Google Scholar
• Zhao J, Kelnar K, Bader AG. In-depth analysis shows synergy between erlotinib and miR-34a. PLoS One. 2014;9:e89105.
   Web of Science ®Google Scholar
• Stahlhut C, Slack FJ. Combinatorial action of microRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation. Cell Cycle. 2015;14:2171–2180.
   PubMed Web of Science ®Google Scholar
• Zhou J-Y, Chen X, Zhao J, et al. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett. 2014;351:265–271.
   PubMed Web of Science ®Google Scholar
• Xue W, Dahlman JE, Tammela T, et al. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA. 2014;111:E3553–E3561.
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Kelnar K, Stahlhut C, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2014;34:3547–3555.
   PubMed Web of Science ®Google Scholar
• Wu J, Wu G, Lv L, et al. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis. 2012;33:519–528.
   PubMed Web of Science ®Google Scholar
• Nugent M, Miller N, Kerin MJ. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol. 2012;106:947–952.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang P, Li Y, et al. The quantitative analysis by stem-loop real-time PCR revealed the microRNA-34a, microRNA-155 and microRNA-200c overexpression in human colorectal cancer. Med Oncol. 2012;29:3113–3118.
   PubMed Web of Science ®Google Scholar
• Vogt M, Munding J, Grüner M, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 2011;458:313–322.
   PubMed Web of Science ®Google Scholar
• Siemens H, Neumann J, Jackstadt R, et al. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer. Clin Cancer Res. 2013;19:710–720.
   PubMed Web of Science ®Google Scholar
• Dandawate P, Padhye S, Ahmad A, et al. Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv Transl Res. 2013;3:165–182.
   PubMed Web of Science ®Google Scholar
• Akao Y, Khoo F, Kumazaki M, et al. Extracellular disposal of tumor-suppressor miRs-145 and −34a via microvesicles and 5-FU resistance of human colon cancer cells. Int J Mol Sci. 2014;15:1392–1401.
   PubMed Web of Science ®Google Scholar
• Meng F, Glaser SS, Francis H, et al. Epigenetic regulation of miR-34a expression in alcoholic liver injury. Am J Pathol. 2012;181:804–817.
   PubMed Web of Science ®Google Scholar
• Chen H, Sun Y, Dong R, et al. Mir-34a is upregulated during liver regeneration in rats and is associated with the suppression of hepatocyte proliferation. PLoS One. 2011;6:e20238.
   Web of Science ®Google Scholar
• Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275:44–53.
   PubMed Web of Science ®Google Scholar
• Sukata T, Sumida K, Kushida M, et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett. 2011;200:46–52.
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhou L, Xie Q-F, et al. The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics. 2010;10:1557–1572.
   PubMed Web of Science ®Google Scholar
• Seol D-W, Chen Q, Smith ML, et al. Regulation of the c-met proto-oncogene promoter by p53. J Biol Chem. 1999;274:3565–3572.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–1380.
   PubMed Web of Science ®Google Scholar
• Bandi N, Vassella E. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011;10:55.
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu C, Liu X, et al. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One. 2014;9:e90022.
   Google Scholar
• Gallardo E, Navarro A, Viñolas N, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903–1909.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen Z, Gao Y, et al. DNA hypermethylation of microRNA-34b/c has prognostic value for stage I non-small cell lung cancer. Cancer Biol Ther. Landes Bioscience. 2011;11:490–496.
   PubMed Web of Science ®Google Scholar
• Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008;7:2591–2600.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:0225–0235.
   Web of Science ®Google Scholar
• Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther J Am Soc Gene Ther. Nature Publishing Group. 2011;19:1116–1122.
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res. 2012;72:5576–5587.
   PubMed Web of Science ®Google Scholar
• Daige CL, Wiggins JF, Priddy L, et al. Systemic delivery of a miR-34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther. 2014;13:2352–2360.
   PubMed Web of Science ®Google Scholar
• Tazawa H, Tsuchiya N, Izumiya M, et al. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci. 2007;104:15472–15477.
   PubMed Web of Science ®Google Scholar
• Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518:107–110.
   PubMed Web of Science ®Google Scholar
• Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8:R59.
   PubMed Web of Science ®Google Scholar
• Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin. Dev. Immunol. 2012;2012:708036–708046.
   PubMedGoogle Scholar
• Zhou J, Rossi JJ. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol Ther Nucleic Acids. 2014;3:e169.
   PubMedGoogle Scholar
• Li W-MW-M-M, Bing T, Wei J-Y-YJ-Y, et al. Cell-SELEX-based selection of aptamers that recognize distinct targets on metastatic colorectal cancer cells. Biomaterials. 2014;35:6998–7007.
   PubMed Web of Science ®Google Scholar
• Huang Y, Qi Y, Du J-Q, et al. MicroRNA-34a regulates cardiac fibrosis after myocardial infarction by targeting Smad4. Expert Opin Ther Targets. 2014;18:1355–1365.
   PubMed Web of Science ®Google Scholar
• Smit-McBride Z, Forward KI, Nguyen AT, et al. Age-dependent increase in miRNA-34a expression in the posterior pole of the mouse eye. Mol Vis. 2014;20:1569–1578.
   PubMed Web of Science ®Google Scholar
• Lovis P, Roggli E, Laybutt DR, et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes. 2008;57:2728–2736.
   PubMed Web of Science ®Google Scholar
• Backe MB, Novotny GW, Christensen DP, et al. Altering beta-cell number through stable alteration of miR-21 and miR-34a expression. Islets. 2014;6:e27754.
   PubMed Web of Science ®Google Scholar
• Jiang P, Liu R, Zheng Y, et al. MiR-34a inhibits lipopolysaccharide-induced inflammatory response through targeting Notch1 in murine macrophages. Exp Cell Res. 2012;318:1175–1184.
   PubMed Web of Science ®Google Scholar
• Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.
   PubMedGoogle Scholar
• Li L, Xie X, Luo J, et al. Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther. 2012;20:2326–2334.
   Web of Science ®Google Scholar